Spots Global Cancer Trial Database for malignant lymphoma
Every month we try and update this database with for malignant lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma | NCT00389051 | Non-Hodgkin's L... | bendamustine hy... | 20 Years - 75 Years | SymBio Pharmaceuticals | |
| A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation | NCT05545202 | Malignant Lymph... Multiple Myelom... | Pentaisomaltose | 18 Years - | Pharmacosmos A/S | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma | NCT01789060 | Malignant Lymph... P13K-AKT Pathwa... | p-AKT immunohis... | 17 Years - 90 Years | Samsung Medical Center | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Music & Cancer - Live Music During Chemotherapy | NCT01870479 | Non Hodgkin´s L... Hodgkin´s Lymph... | Live music Taped music | 18 Years - | University of Southern Denmark | |
| Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | NCT01588548 | Advanced Solid ... Malignant Lymph... | AZD1208 | 18 Years - 130 Years | AstraZeneca | |
| Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study | NCT02678299 | Malignant Lymph... | PREBEN | 18 Years - 85 Years | University of Aarhus | |
| CPAP or BiPAP for Motion Mitigation During Radiotherapy | NCT04986293 | Radiotherapy Si... NSCLC Esophageal Canc... Malignant Lymph... | CPAP | 18 Years - | University Medical Center Groningen | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma | NCT03316144 | Malignant Lymph... | Toripalimab | 18 Years - 65 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Phase I Study of Mitoxantrone Hydrochloride Liposome Injection | NCT02131688 | Malignant Lymph... | Mitoxantrone Hy... | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas | NCT00685997 | Malignant Lymph... Hodgkin's Disea... Non-Hodgkin's L... | 8 Years - | UMC Utrecht | ||
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | NCT05515029 | Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom... | GVHD prevention... | 1 Day - 21 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324310 | Hematologic Mal... Malignant Lymph... | Romidepsin Ketoconazole | 18 Years - | Celgene | |
| Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden | NCT04760184 | Covid19 Myeloma Multipl... Malignant Lymph... Hematologic Neo... Stem Cell Trans... | Autologous stem... | 18 Years - | Uppsala University | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | NCT04464889 | Acute Myeloid L... Acute Lymphoid ... Myelodysplastic... Myeloproliferat... Chronic Myeloid... Myelofibrosis Multiple Myelom... Malignant Lymph... | MDG1021 dose 1 MDG1021 dose 2 MDG1021 dose 3 MDG1021 optimal... | 18 Years - | Medigene AG | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials | NCT05827341 | Malignant Lymph... Clinical Trial COVID-19 | No intervention | 18 Years - 80 Years | Sun Yat-sen University | |
| Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? | NCT00892502 | Hematological D... Hematological M... Blood Diseases Malignant Lymph... Leukemia Multiple Myelom... | Bismuth tablets Placebo tablets | 18 Years - 75 Years | Copenhagen University Hospital at Herlev | |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | NCT05515029 | Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom... | GVHD prevention... | 1 Day - 21 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| EchoTip AcuCore Post-Market Clinical Study | NCT06358001 | Adenocarcinoma Neuroendocrine ... Hepatocellular ... Cholangiocarcin... Malignant Lymph... Metastasis Chronic Pancrea... Autoimmune Panc... | EchoTip AcuCore | 18 Years - | Cook Group Incorporated | |
| EchoTip AcuCore Post-Market Clinical Study | NCT06358001 | Adenocarcinoma Neuroendocrine ... Hepatocellular ... Cholangiocarcin... Malignant Lymph... Metastasis Chronic Pancrea... Autoimmune Panc... | EchoTip AcuCore | 18 Years - | Cook Group Incorporated |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
